港股10只倍升潜力股:创新药BD×新质生产力×低估重估(2026-08-10)
* { margin: 0; padding: 0; box-sizing: border-box; } body { background: #0f1222; color: #dde2f5; font-family: "PingFang
量化策略、技术分析与交易系统
* { margin: 0; padding: 0; box-sizing: border-box; } body { background: #0f1222; color: #dde2f5; font-family: "PingFang
* { margin: 0; padding: 0; box-sizing: border-box; } body { background: #0f1222; color: #dde2f5; font-family: "PingFang
* { margin: 0; padding: 0; box-sizing: border-box; } body { background: #0f1222; color: #dde2f5; font-family: "PingFang
* { margin: 0; padding: 0; box-sizing: border-box; } body { background: #0f1222; color: #dde2f5; font-family: "PingFang
* { margin: 0; padding: 0; box-sizing: border-box; } body { font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI',
* { margin: 0; padding: 0; box-sizing: border-box; } body { font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI',
扩展为五只精选标的:中信股份、人保、携程、中国宏桥与SK hynix,覆盖资产重估、防御、平台成长、周期分红和AI存储成长。